These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214 [TBL] [Abstract][Full Text] [Related]
47. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Lainer-Carr D; Brahn E Nat Clin Pract Rheumatol; 2007 Aug; 3(8):434-42. PubMed ID: 17664950 [TBL] [Abstract][Full Text] [Related]
48. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology]. Mross K Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270 [No Abstract] [Full Text] [Related]
49. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Shojaei F; Ferrara N Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057 [TBL] [Abstract][Full Text] [Related]
50. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy. Sato Y Cancer Sci; 2011 Jul; 102(7):1253-6. PubMed ID: 21401807 [TBL] [Abstract][Full Text] [Related]